Rhumbline Advisers Has $16.70 Million Stock Holdings in Glaukos Co. (NYSE:GKOS)

Rhumbline Advisers increased its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 3.7% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 141,091 shares of the medical instruments supplier's stock after purchasing an additional 5,079 shares during the period. Rhumbline Advisers owned approximately 0.28% of Glaukos worth $16,698,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its position in Glaukos by 17.9% in the 4th quarter. Russell Investments Group Ltd. now owns 17,891 shares of the medical instruments supplier's stock worth $1,422,000 after purchasing an additional 2,715 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Glaukos by 7.8% in the 4th quarter. Victory Capital Management Inc. now owns 19,763 shares of the medical instruments supplier's stock valued at $1,571,000 after acquiring an additional 1,426 shares in the last quarter. Fisher Asset Management LLC bought a new stake in shares of Glaukos in the 4th quarter worth approximately $216,000. Natixis Advisors L.P. grew its holdings in shares of Glaukos by 14.5% during the 4th quarter. Natixis Advisors L.P. now owns 38,920 shares of the medical instruments supplier's stock worth $3,093,000 after purchasing an additional 4,941 shares in the last quarter. Finally, National Bank of Canada FI bought a new stake in shares of Glaukos during the fourth quarter valued at approximately $46,000. Institutional investors own 99.04% of the company's stock.

Analyst Ratings Changes

Several brokerages recently commented on GKOS. StockNews.com cut Glaukos from a "hold" rating to a "sell" rating in a research report on Friday, August 30th. Stifel Nicolaus upped their target price on shares of Glaukos from $130.00 to $145.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Piper Sandler upped their price objective on Glaukos from $110.00 to $140.00 and gave the company an "overweight" rating in a research note on Thursday, August 1st. BTIG Research increased their target price on Glaukos from $131.00 to $139.00 and gave the stock a "buy" rating in a report on Wednesday, August 28th. Finally, Wells Fargo & Company boosted their price target on Glaukos from $120.00 to $135.00 and gave the company an "overweight" rating in a research note on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $129.82.

Insider Activity

In other Glaukos news, COO Joseph E. Gilliam sold 5,000 shares of the company's stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total transaction of $646,800.00. Following the transaction, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $13,216,581.84. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Glaukos news, COO Joseph E. Gilliam sold 5,000 shares of Glaukos stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total transaction of $646,800.00. Following the completion of the sale, the chief operating officer now owns 102,169 shares of the company's stock, valued at approximately $13,216,581.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Joseph E. Gilliam sold 2,250 shares of the stock in a transaction on Friday, July 5th. The shares were sold at an average price of $121.39, for a total value of $273,127.50. Following the completion of the transaction, the chief operating officer now directly owns 101,845 shares in the company, valued at approximately $12,362,964.55. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,500 shares of company stock valued at $4,706,990. Company insiders own 6.40% of the company's stock.

Glaukos Price Performance

Shares of Glaukos stock traded down $3.70 during trading on Tuesday, reaching $125.70. The company's stock had a trading volume of 661,644 shares, compared to its average volume of 585,729. The stock has a 50-day moving average price of $124.18 and a two-hundred day moving average price of $109.64. The stock has a market capitalization of $6.91 billion, a P/E ratio of -43.65 and a beta of 1.02. The company has a current ratio of 5.48, a quick ratio of 4.67 and a debt-to-equity ratio of 0.19. Glaukos Co. has a one year low of $59.22 and a one year high of $136.60.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) EPS for the quarter, meeting the consensus estimate of ($0.52). Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The business had revenue of $95.70 million for the quarter, compared to analysts' expectations of $88.86 million. During the same period in the prior year, the firm earned ($0.55) earnings per share. Glaukos's revenue was up 19.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Glaukos Co. will post -2.18 EPS for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.